115563
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
玻璃体后脱离决定增殖性糖尿病视网膜病变抗血管内皮生长因子治疗后纤维血管膜纤维化的临床影响：一项真实世界研究
Authors Zhao M , Wang Z, Liu L, O'Toole L , Li J
Received 17 July 2025
Accepted for publication 9 December 2025
Published 7 January 2026 Volume 2026:20 554446
DOI https://doi.org/10.2147/OPTH.S554446
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Yousef Fouad
Meng Zhao,1 Zhaoyang Wang,1,* Lin Liu,1,* Louise O’Toole,2 Jipeng Li1
1Department of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Department of Ophthalmology, Mater Misericordiae University Hospital, Dublin, Ireland
*These authors contributed equally to this work
Correspondence: Jipeng Li, Department of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China, Email jipeng2004@sina.com
Purpose: To investigate the relationship between posterior vitreous detachment (PVD) status and fibrovascular membrane (FVM) angio-fibrotic transformation following anti-VEGF therapy in advanced proliferative diabetic retinopathy (PDR), and their combined impact on disease progression and visual outcomes.
Methods: This prospective real-world study enrolled 165 treatment-naïve PDR patients with vitreous hemorrhage (VH) and FVM who received intravitreal anti-VEGF injection followed by panretinal photocoagulation(PRP) when possible. PVD status and FVM characteristics were monitored during a median follow-up of 13.0 months. Cox proportional hazards and Kaplan-Meier analyses evaluated factors influencing visual prognosis and timing of surgical intervention.
Results: FVM fibrosis occurred in 43% of patients, with distinct PVD-dependent patterns: predominantly in complete PVD cases, moderately in partial PVD, and rarely without PVD. Multivariate analysis identified macular involvement as the strongest risk factor for poor visual outcomes (HR=3.65), while PVD (HR=0.37) and FVM fibrosis (HR=0.023) were strongly protective. Patients with both PVD and FVM fibrosis maintained stable vision longest (median 28.5 months) and demonstrated significantly longer surgery-free survival (28.3 months) compared to those without either condition (3.2 months, p< 0.0001), who frequently presented with vitreoschisis and recurrent VH disproportionate to visible FVM grade.
Conclusion: PVD status critically determines the clinical manifestation and prognosis of post-anti-VEGF FVM fibrosis in PDR. This PVD-dependent pattern challenges the conventional view that FVM fibrosis inevitably leads to “Crunch syndrome” and creates a risk stratification framework that can guide individualized surgical timing decisions, potentially improving functional outcomes in advanced PDR.
Plain Language Summary: Proliferative diabetic retinopathy (PDR) is a serious complication of diabetes and a leading cause of blindness. It often involves the growth of abnormal blood vessels and membranes inside the eye, which can cause severe vision problems. Doctors frequently treat this condition by injecting medications called anti-VEGF agents, which slow the growth of these harmful vessels. However, sometimes these treatments cause the abnormal vessels and membranes to become fibrotic—meaning they harden and contract, potentially causing further issues.
This study aimed to understand how a condition called posterior vitreous detachment (PVD), where the gel-like substance in the eye separates from the retina, influences the outcomes after anti-VEGF treatment. Researchers observed 165 patients with severe PDR who received anti-VEGF injections and monitored how their conditions changed over approximately one year.
The study found that nearly half the patients experienced membrane fibrosis after treatment. Importantly, patients with a complete vitreous detachment showed better results, including less tractional damage to the retina and longer periods without needing surgery. Conversely, patients without vitreous detachment faced more severe complications, needed surgery sooner, and had worse vision outcomes.
These results indicate that the presence of a vitreous detachment significantly impacts whether fibrosis will be beneficial or harmful after treatment. Understanding this relationship helps doctors predict outcomes more accurately and plan treatments better. Ultimately, this could lead to improved vision preservation and fewer surgical interventions for people with severe diabetic retinopathy.
Keywords: proliferative diabetic retinopathy, real world study, posterior vitreous detachment, anti-VEGF, fibrovascular membrane
1Department of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Department of Ophthalmology, Mater Misericordiae University Hospital, Dublin, Ireland
*These authors contributed equally to this work
Correspondence: Jipeng Li, Department of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China, Email jipeng2004@sina.com
Purpose: To investigate the relationship between posterior vitreous detachment (PVD) status and fibrovascular membrane (FVM) angio-fibrotic transformation following anti-VEGF therapy in advanced proliferative diabetic retinopathy (PDR), and their combined impact on disease progression and visual outcomes.
Methods: This prospective real-world study enrolled 165 treatment-naïve PDR patients with vitreous hemorrhage (VH) and FVM who received intravitreal anti-VEGF injection followed by panretinal photocoagulation(PRP) when possible. PVD status and FVM characteristics were monitored during a median follow-up of 13.0 months. Cox proportional hazards and Kaplan-Meier analyses evaluated factors influencing visual prognosis and timing of surgical intervention.
Results: FVM fibrosis occurred in 43% of patients, with distinct PVD-dependent patterns: predominantly in complete PVD cases, moderately in partial PVD, and rarely without PVD. Multivariate analysis identified macular involvement as the strongest risk factor for poor visual outcomes (HR=3.65), while PVD (HR=0.37) and FVM fibrosis (HR=0.023) were strongly protective. Patients with both PVD and FVM fibrosis maintained stable vision longest (median 28.5 months) and demonstrated significantly longer surgery-free survival (28.3 months) compared to those without either condition (3.2 months, p< 0.0001), who frequently presented with vitreoschisis and recurrent VH disproportionate to visible FVM grade.
Conclusion: PVD status critically determines the clinical manifestation and prognosis of post-anti-VEGF FVM fibrosis in PDR. This PVD-dependent pattern challenges the conventional view that FVM fibrosis inevitably leads to “Crunch syndrome” and creates a risk stratification framework that can guide individualized surgical timing decisions, potentially improving functional outcomes in advanced PDR.
Plain Language Summary: Proliferative diabetic retinopathy (PDR) is a serious complication of diabetes and a leading cause of blindness. It often involves the growth of abnormal blood vessels and membranes inside the eye, which can cause severe vision problems. Doctors frequently treat this condition by injecting medications called anti-VEGF agents, which slow the growth of these harmful vessels. However, sometimes these treatments cause the abnormal vessels and membranes to become fibrotic—meaning they harden and contract, potentially causing further issues.
This study aimed to understand how a condition called posterior vitreous detachment (PVD), where the gel-like substance in the eye separates from the retina, influences the outcomes after anti-VEGF treatment. Researchers observed 165 patients with severe PDR who received anti-VEGF injections and monitored how their conditions changed over approximately one year.
The study found that nearly half the patients experienced membrane fibrosis after treatment. Importantly, patients with a complete vitreous detachment showed better results, including less tractional damage to the retina and longer periods without needing surgery. Conversely, patients without vitreous detachment faced more severe complications, needed surgery sooner, and had worse vision outcomes.
These results indicate that the presence of a vitreous detachment significantly impacts whether fibrosis will be beneficial or harmful after treatment. Understanding this relationship helps doctors predict outcomes more accurately and plan treatments better. Ultimately, this could lead to improved vision preservation and fewer surgical interventions for people with severe diabetic retinopathy.
Keywords: proliferative diabetic retinopathy, real world study, posterior vitreous detachment, anti-VEGF, fibrovascular membrane